

RTP On Demand: Current and Future Role of PARP Inhibitors in the Management of Ovarian Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Olaparib monotherapy is FDA approved for patients with deleterious germline BRCA mutation-positive advanced OC previously treated with 3 or more lines of chemotherapy.
a. True
b. False
- For which of the following patients with platinum-sensitive, recurrent OC did the use of niraparib maintenance therapy provide a significant progression-free survival benefit in comparison to placebo on the Phase III ENGOT-OV16/NOVA trial?
a. Patients with germline BRCA mutation
b. Patients with no germline BRCA mutation
c. Patients with no germline BRCA mutation but with HRD positivity
d. All of the above
e. Both a and b
f. Both b and c
- For how long did patients on the Phase III ENGOT-OV16/NOVA trial receive niraparib maintenance therapy?
a. One year
b. Two years
c. Indefinitely (until either disease progression or toxicity)
- The most common cytopenia observed with niraparib on the Phase III ENGOT-OV16/NOVA trial was _____.
a. Anemia
b. Neutropenia
c. Thrombocytopenia
d. All of the above
- The Phase III PAOLA-1 trial is evaluating olaparib in combination with _____ as first-line therapy for advanced OC.
a. Anti-PD-1/PD-L1 inhibition
b. Bevacizumab
c. Cediranib
- Side effects of olaparib therapy include _____.
a. Anemia
b. Nausea
c. Fatigue
d. Vomiting
e. All of the above
- The Phase III SOLO1 trial is evaluating olaparib monotherapy maintenance for patients with _____ advanced OC after first-line platinum-based chemotherapy.
a. BRCA wild-type
b. Germline BRCA mutation-positive
c. Both a and b
- Rucaparib is a novel PARP inhibitor with demonstrated single-agent activity in the treatment of patients with BRCA mutation-positive advanced OC.
a. True
b. False
- The Phase I/II KEYNOTE-162 trial is evaluating niraparib in combination with _____ for patients with recurrent OC or triple-negative breast cancer.
a. Atezolizumab
b. Nivolumab
c. Pembrolizumab
d. All of the above
- It is recommended that _____ undergo BRCA testing.
a. All patients with epithelial OC
b. Patients with an Ashkenazi Jewish background
c. Patients with a strong family history of breast cancer or OC at a young age